Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Kamada Ltd KMDA

Kamada Ltd is Israel based company, focused on plasma-derived protein therapeutics with a commercial product portfolio and a late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune... see more

Recent & Breaking News (NDAQ:KMDA)

Kamada Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares

GlobeNewswire August 30, 2017

18 Biggest Mid-Day Gainers For Friday

Benzinga.com  August 25, 2017

Kedrion Biopharma and Kamada Receive FDA Approval of KEDRAB™ for Post-Exposure Prophylaxis Against Rabies Infection

GlobeNewswire August 25, 2017

Kamada Reports Financial Results for Second Quarter and First Six Months of 2017

GlobeNewswire August 1, 2017

Kamada Announces Pricing of Public Offering of Ordinary Shares

GlobeNewswire July 28, 2017

Kamada Pre-Announces Certain Preliminary Financial Results for Second Quarter and First Six Months of 2017

GlobeNewswire July 27, 2017

Kamada Announces Proposed Public Offering of Ordinary Shares

GlobeNewswire July 27, 2017

Kamada to Host Second Quarter 2017 Financial Results Conference Call on August 1

GlobeNewswire July 27, 2017

Kamada Submits Proposed Phase 3 Protocol to FDA for Inhaled Alpha-1 Antitrypsin for Treatment of Alpha-1 Antitrypsin Deficiency Disease

GlobeNewswire July 20, 2017

Mid-Afternoon Market Update: Steelcase Tumbles Following Disappointing Earnings Report; Staples Shares Surge

Benzinga.com  June 22, 2017

Mid-Day Market Update: Oracle Surges On Earnings Beat; Kamada Shares Plummet

Benzinga.com  June 22, 2017

Mid-Morning Market Update: Markets Mostly Flat; Accenture Posts In-Line Q3 Earnings

Benzinga.com  June 22, 2017

Kamada Announces Withdrawal of European Marketing Authorization Application for Inhaled Alpha-1 Antitrypsin for Treatment of Alpha-1 Antitrypsin Deficiency Disease

GlobeNewswire June 22, 2017

Kamada Receives Additional Milestone Payment Under GLASSIA® Exclusive Supply and Distribution Agreement with Shire

GlobeNewswire June 12, 2017

15 Biggest Mid-Day Losers For Wednesday

Benzinga.com  June 7, 2017

Kamada Provides Update on Clinical Program for Alpha-1 Antitrypsin IV for Treatment of Graft-Versus-Host Disease

GlobeNewswire June 7, 2017

Kamada Announces Appointment of Michal Stein, M.D., as Vice President and Medical Director

GlobeNewswire June 5, 2017

Kamada Presents Updated Data from Phase 2 Clinical Trial of Inhaled Alpha-1-Antitrypsin for Treatment of Alpha-1 Antitrypsin Deficiency at 2017 American Thoracic Society International Conference

GlobeNewswire May 24, 2017

Investor Network: Kamada Ltd to Host Earnings Call

Accesswire May 16, 2017

Kamada Reports 2017 First Quarter Financial Results

GlobeNewswire May 16, 2017